Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome

Blood Transfusion

Volumn 15, Issue 5, 2017, Pages 472-477

  Ortiz, Sebastián ^a   Orero, Maria T ^a   Javier, Karla ^a   Villegas, Carolina ^a   Luna, Irene ^a   Pérez, Pedro ^a   Roig, Mónica ^a   López, María ^a   Costa, Sofía ^a   Carbonell, Félix ^a   Collado, Rosa ^a   Ivars, David ^a   Linares, Mariano ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Alloimmunisation; Azacitidine; Myelodysplastic syndrome

Indexed keywords

ALLOANTIBODY; AZACITIDINE; ERYTHROCYTE ANTIBODY; RHESUS C ANTIBODY; RHESUS D ANTIBODY; RHESUS E ANTIBODY; RHESUS K ANTIBODY; RHESUS LUA ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY;

ADULT; AGE; AGED; ALLOIMMUNIZATION; ANTIBODY SCREENING; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECONDARY ACUTE MYELOID LEUKEMIA; SEX; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; BLOOD TRANSFUSION REACTION; CHEMICALLY INDUCED; ERYTHROCYTE; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AZACITIDINE; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HUMANS; IMMUNIZATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSFUSION REACTION;

EID: 85026634818     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2016.0012-16     Document Type: Article

References (25)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-32.
2. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-9.
3. Sanz C, Nomdedeu M, Belkaid M., et al. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion 2013; 53: 710-5.
4. Novaretti MC, Sopelete CR, Velloso E.R., et al. Immunohematological findings in myelodysplastic syndrome. Acta Haematol 2001; 105: 1-6
5. Stiegler G, Sperr W, Lorber C., et al. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol 2001; 80: 330-3.
6. Arriaga F, Bonanad S, Larrea L., et al. [Immunohematologic study in 112 patients with myelodysplastic syndromes: 10-year analysis]. Sangre (Barc) 1995; 40: 177-80. [In Spanish.]
7. Al Ustwani O., Ford LA, Sait S.J., et al. Myelodysplastic syndromes and autoimmune diseases case series and review of literature. Leuk Res 2013; 37: 894-9.
8. Ryder AB, Hendrickson JE, Tormey CA Chronic inflammatory autoinmmune disorders are a risk factor for red blood cell alloimmunization. Br J Haematol 2016; 174: 483-5.
9. Al Ustwani O., Francis J, Wallace P.K., et al. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. Leuk Res 2011; 35: e35-6.
10. Pilorge S, Doleris LM, Dreyfus F, Park S. The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases. Br J Haematol 2011; 153: 664-5.
11. Tanaka H, Shimizu N, Tougasaki E., et al. Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome. Int J Hematol 2013; 97: 520-4.
12. Bauer MP, Wiersum-Osselton J, Schipperus M., et al. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007; 47: 2066-71.
13. Fasano RM, Booth GS, Miles M, et al Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol 2015; 168: 291-300.
14. Zalpuri S, Zwaginga JJ, le Cessie S, et al. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012; 102: 144-9.
15. Gehrie E, Tormey CA The influence of clinical and biological factors on transfusion-associated non-ABO antigen alloimmunization: responders, hyper-responders, and non-responders. Transfus Med Hemother 2014; 41: 420-9.
16. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999; 39: 763-71.
17. Zalpuri S, Evers D, Zwaginga J.J., et al. Immunosuppressants and alloimmunization against red blood cell transfusions. Transfusion 2014; 54: 1981-7.
18. Perseghin P, Balduzzi A, Galimberti S., et al. Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 231-6.
19. Fluit CR, Kunst VA, Drenthe-Schonk AM. Incidence of red cell antibodies after multiple blood transfusion. Transfusion 1990; 30: 532-5.
20. Verduin EP, Brand A, Mddelburg R.A., Schonewille H. Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion. Transfusion 2015; 55: 1478-85.
21. Cid J, Lozano M, Ziman A., et al. Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study. Br J Haematol 2015; 168; 598-603.
22. Gonzalez-Porras J.R., Graciani IF, Pérez-Simon JA, et al. Prospective evaluation of a transfusion policy of D+ red blood cells into D-patients. Transfusion 2008; 48: 1318-24.
23. Schonewille H, Honohan Á, van der Watering LM, et al. Incidence of alloantibody formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH study). Transfusion 2016; 56: 311-20.
24. Lasalle-Williams M., Nuss R, Le T., et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 2011; 51: 1732-9.
25. th Annual Meeting of the American Society of Hematology; 2015 [Abstract 3562].